While several reports assign Cx43 an oncosuppressor feature, recent findings have revealed an opposite role: ongoing research demonstrates that Cx43 is highly expressed in GBM, especially in GSCs, conferring a survival advantage to tumor cells [15–19]. This evidence concerns the gene GJA1 and glioblastoma.